Global Finance News
30 Oct 2025, 14:09
Biogen Posts Strong Q3 Results, Raises 2025 Outlook on Launch Product Momentum
Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3% year over year, with GAAP diluted EPS rising 19% to $3.17 and non-GAAP EPS up 18% to $4.81. Growth was driven by a 67% surge in newer products, including LEQEMBI, SKYCLARYS, and ZURZUVAE. Alzheimer’s drug LEQEMBI generated $121 million in global sales, while SKYCLARYS reached $133 million and ZURZUVAE $55 million. The MS franchise grew 1% on U.S. strength in VUMERITY. Biogen advanced key pipeline programs, including FDA resubmission for high-dose SPINRAZA and full enrollment of two Phase 3 litifilimab lupus studies. The company raised its 2025 non-GAAP EPS guidance to $14.50–$15.00 and now expects total revenue to be flat to up 1% year over year.
Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3% year over year, with GAAP diluted EPS rising 19% to $3.17 and non-GAAP EPS up 18% to $4.81. Growth was driven by a 67% surge in newer products, including LEQEMBI, SKYCLARYS, and ZURZUVAE. Alzheimer’s drug LEQEMBI generated $121 million in global sales, while SKYCLARYS reached $133 million and ZURZUVAE $55 million. The MS franchise grew 1% on U.S. strength in VUMERITY. Biogen advanced key pipeline programs, including FDA resubmission for high-dose SPINRAZA and full enrollment of two Phase 3 litifilimab lupus studies. The company raised its 2025 non-GAAP EPS guidance to $14.50–$15.00 and now expects total revenue to be flat to up 1% year over year.
